SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending due to reports of a significant multi-billion dollar debt financing deal for a data center project alongside broader community debate regarding the firm's AI infrastructure strategy and debt levels. Investors remain deeply divided, with some betting on a technical turnaround from recent lows while others express frustration over persistent downward price pressure and valuation concerns.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing a massive rally and significant investor attention driven by strong NAND demand and its upcoming inclusion in the Nasdaq-100, which has fueled widespread debate over whether the stock is undergoing a sustainable AI-driven re-rating or forming a bubble. Community sentiment remains deeply divided, with many bulls anticipating a stock split and further gains toward the $1,000 level, while a vocal group of bears warns of an imminent rug pull due to extreme valuation levels.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is currently a focal point for retail investors who are actively debating the potential for a short squeeze, driven by significant short interest and speculation regarding a possible buyout or leadership change. While some in the community remain bullish on the brand's international expansion and dividend yield, others express frustration over the stock's persistent downtrend and the lack of a permanent CEO.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Guy is gaining significant traction as the community highlights its status as a foundational internet meme, bolstered by the acquisition and restoration of original tools like RageMaker. Supporters are actively engaging in daily "bag working" and meme creation, framing the project as a resilient, culture-backed alternative to temporary meme coin trends.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors rally behind a multi-million dollar government contract win that validates the potential of its semiconductor platform for quantum and high-speed data communications. The community is actively debating the company's long-term commercialization prospects and its ability to scale manufacturing through strategic partnerships while monitoring recent insider activity and price volatility.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding is currently trending due to a federal securities fraud lawsuit the company filed against several financial institutions, alleging they misappropriated Datavault AI collateral shares to manipulate the stock. Investors are actively debating the company's financial viability, its reliance on debt financing, and potential bankruptcy risks, while the community remains divided between those expecting a breakthrough with its non-opioid pipeline and critics warning of past leadership failures and fiscal mismanagement.

Conagra Brands, Inc. engages in the manufacture and sale of processed and packaged foods. It operates through the following segments: Grocery and Snacks, Refrigerated and Frozen, International, and Foodservice. The Grocery and Snacks segment includes branded, and shelf stable food products sold in various retail channels in the United States. The Refrigerated and Frozen segment is composed of branded, and temperature-controlled food products sold in various retail channels in the United States. The International segment offers branded food products in various temperature states, sold in various retail and foodservice channels outside of the United States. The Foodservice segment focuses on branded and customized food products, including meals, entrees, sauces, and a variety of custom-manufactured culinary products packaged for sale to restaurants and other foodservice establishments in the United States. The company was founded by Alva Kinney and Frank Little in 1919 and is headquartered in Chicago, IL.

Conagra Brands Inc

Conagra Brands is experiencing a significant leadership transition with the appointment of John Brase as CEO, a move that has sparked intense debate among investors regarding the company's future operational strategy. While the stock has faced downward pressure and concerns over dividend sustainability, the community remains deeply divided between those viewing the current valuation as a prime long-term value opportunity and those cautioning against ongoing margin and volume challenges.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is trending following the resignation of its top lawyer due to surfaced ties to Jeffrey Epstein, creating volatility in shares while the stock continues to navigate the broader financial sector's earnings season and macro headwinds. The community is actively debating the stock's stability amid these legal revelations, the potential for a pullback to key technical support levels, and the company's aggressive pivot toward private credit and wealth management.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest a highly anticipated positive data readout for its Phase 3 study in metastatic pancreatic cancer. The community is focused on the drug's potential to significantly improve survival outcomes for a historically difficult-to-treat disease, sparking widespread discussion about its long-term commercial potential and M&A prospects.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending due to a surge in market sentiment and institutional upgrades, with investors actively discussing potential long-term growth driven by new data center partnerships and its role in domestic AI infrastructure. Community discourse is highly polarized, featuring both optimistic bulls targeting new price highs based on momentum and strategic pivots, and skeptical bears debating the stock's valuation, high debt levels, and the sustainability of its recent rapid price appreciation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revolution Medicines (NASDAQ:RVMD) Hits New 52-Week High  - Here's Why

Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year High - Here's Why...

Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.read more...

Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo

Revolution Medicines stock rises after Phase 3 daraxonrasib data show survival gains in pancreatic cancer, with regulatory filings planned.read more...

Revolution Medicines Stock Rises 39% Over Positive Topline Data From Daraxonrasib Study

(RTTNews) - Shares of Revolution Medicines, Inc. (RVMD) are climbing about 39 percent on Monday morning trading after the company announced positive topline data from the Phase 3 RASolute trial for Daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma...

<ul class="summary-bullets"><li>Daraxonrasib significantly improved both progression-free and overall survival compared to standard chemotherapy.</li><li>Patients treated with the drug lived a median of 13.2 months, compared with 6.7 months for those on chemotherapy.</li><li>The firm stated that the study met all key endpoints.</li></ul>Revolution Medicines (RVMD) drew the spotlight after its shares surged 36% on Monday morning, driven by strong Phase 3 results for its experimental drug Daraxonrasib to treat metastatic pancreatic cancer.<h2 class="st-heading-2">Trial Shows Better Results Than Standard Chemotherapy</h2>In the RASolute 302 trial, Daraxonrasib significantly improved both progression-free and overall survival compared to standard chemotherapy. Patients treated with the drug lived a median of 13.2 months, compared with 6.7 months for those on chemotherapy, highlighting a meaningful benefit. The treatment was also generally well tolerated, with no new safety concerns reported.The study met all key endpoints, and the company plans to submit the data to the U.S. Food and Drug Administration (FDA) and present it at the American Society of Clinical Oncology Annual Meeting in May.“These results represent a potentially transformative advance for patients and underscore daraxonrasib’s potential to redefine the treatment landscape,” said Mark A. Goldsmith, CEO and chairman of Revolution Medicines.<h2 class="st-heading-2">Daraxonrasib Targets RAS-Driven Tumors</h2>Pancreatic cancer is heavily driven by RAS gene mutations, with over 90% of patients affected by these aggressive genetic changes. Daraxonrasib is a new drug designed to target a broad range of RAS-driven tumors.In the trial, patients received either a daily oral dose of Daraxonrasib or standard chemotherapy chosen by doctors. The study mainly measured progression-free and overall survival in patients with specific RAS mutations, while also tracking results across all participants. It also evaluated response rates, duration of benefit, and quality of life.While Daraxonrasib has not yet been approved in the U.S. or Europe, it has received special designations from the FDA to expedite its development for pancreatic cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/RVMD">RVMD</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ amid ‘extremely high’ message volumes.Users spoke about a potential buyout following the results.<stembedurl>https://stocktwits.com/TH76/message/650101082</stembedurl><stembedurl>https://stocktwits.com/Ccg_/message/650101993</stembedurl>RVMD shares have gained more than 220% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Revolution Medicines company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

RVMD Stock Surges To All-Time Highs After 36% Jump – What’s Driving This Super Rally?

The company reported robust Phase 3 results for its Daraxonrasib drug to treat metastatic pancreatic cancer.

Equity

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial...

Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer

Former Sen. Ben Sasse is taking Revolution Medicines' daraxonrasib, which has shown promise as a treatment for pancreatic cancer...

Revolution Medicines Target of Unusually Large Options Trading (NASDAQ:RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) was the target of some unusual options trading activity on Friday. Investors acquired 25,539 put options on the company. This represents an...

Aberdeen Group plc Makes New $9.02 Million Investment in Revolution Medicines, Inc. $RVMD

Aberdeen Group plc purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and...

Tema Etfs LLC Decreases Position in Revolution Medicines, Inc. $RVMD

Tema Etfs LLC trimmed its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 20.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange...

Warranted - fundamentals justify the decline

Overdone - the market is overreacting

Too early to tell

Is the selloff in software stocks warranted or overdone?

Stocktwits

Stocktwits Polls

Massive momentum following pivotal Phase 3 results showing doubled survival rates in pancreatic cancer patients.

Investors are actively debating the high probability of a multi-billion dollar acquisition after de-risked clinical data.

Traders are comparing valuation metrics against biotech peers to justify significant upward price target revisions.

Anticipation of a gamma squeeze is building as traders look for volume-led breakouts to push shares toward $200.

Analysts and enthusiasts are mapping out the competitive landscape for targeting 'undruggable' mutations in oncology.

Current Price	$133.76
Prev Close	$96.43
Open	$132.32
Dividend Yield	0.00%
50-Day Moving Average	$98.11
Beta	1.09
Avg. Volume	1.93M
PE Ratio	-16.30

52-Week High	$124.49
52-Week Low	$34.00
Market Capitalization	$19.11B
EPS (Annual)	-$5.95
Price to Book	11.65
Revenue Per Employee	$0.00

RVMD
Revolution Medicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RVMD News

RVMDRevolution Medicines Inc